When did the USPTO implement the Sequence Listing XML requirement?
The USPTO implemented the Sequence Listing XML requirement for patent applications filed on or after July 1, 2022. This is clearly stated in the editor’s note of MPEP 2419.01: “[Editor Note: This section is applicable to all applications filed on or after July 1, 2022, having disclosures of nucleotide and/or amino acid sequences as defined…
Read MoreWhat happens to Sequence Listing XML files that exceed the 600KB limit?
While MPEP 2419.01 does not explicitly state what happens to Sequence Listing XML files that exceed the 600KB limit when transformed into ASCII text, it implies that these larger files are treated differently: “Upon transformation of the .xml file using the style sheet to an ASCII text file, any ASCII text file produced by the…
Read MoreHow does the USPTO determine if a Sequence Listing XML is “non-lengthy”?
The USPTO determines if a Sequence Listing XML is “non-lengthy” based on the size of the ASCII text file produced after transforming the XML file. According to MPEP 2419.01: “Upon transformation of the .xml file using the style sheet to an ASCII text file, any ASCII text file produced by the USPTO that is under…
Read MoreWhat is a non-lengthy “Sequence Listing XML” in patent applications?
A non-lengthy “Sequence Listing XML” in patent applications refers to an XML file containing nucleotide and/or amino acid sequence information that, when transformed into an ASCII text file using a style sheet, results in a file size under 600KB. According to MPEP 2419.01, these non-lengthy sequence listings are published as part of the patent specification:…
Read MoreNo Additional FAQs Available
All relevant information from MPEP 2419.01 – Patent Grants and Patent Application Publications Containing a Non-Lengthy “Sequence Listing XML” has been covered in the previously generated FAQs. No additional meaningful questions can be created without redundancy. To learn more: Sequence Listing XML Patent Grants Patent Application Publications
Read More